Systemic Lupus Erythematosus: Pathophysiology and Treatment
Pathophysiology
SLE is a chronic autoimmune disease driven by loss of immune tolerance to nuclear antigens, resulting in autoantibody production (particularly anti-dsDNA and anti-Smith antibodies), immune complex formation and deposition in tissues, and type I interferon-driven inflammation 1, 2. The disease involves dysregulation of both innate and adaptive immunity—B cells produce pathogenic autoantibodies, T cells lose regulatory function, and dendritic cells overproduce type I interferons, creating a self-perpetuating inflammatory cascade 2, 3. These immune complexes accumulate in blood vessels and organs (particularly kidneys, skin, joints, and brain), triggering complement activation and tissue damage 4.
The breakdown of self-tolerance is central: genetic susceptibilities combine with environmental triggers (UV light, infections, certain medications) to initiate disease in predisposed individuals, predominantly women of reproductive age 1, 2.
Treatment Approach
Core Treatment Principles
Hydroxychloroquine (HCQ) is the backbone therapy for ALL patients with SLE unless contraindicated 5. This is non-negotiable—HCQ prevents infections, thrombosis, and improves survival 6. The dose should not exceed 5 mg/kg of real body weight 5.
The primary treatment goal is achieving remission or low disease activity with the lowest possible glucocorticoid dose 5. The 2024 EULAR update now recommends maintenance glucocorticoids be minimized to less than 5 mg/day prednisone equivalent (lowered from the previous 7.5 mg/day threshold), as chronic glucocorticoid use correlates with infections, osteonecrosis, and irreversible organ damage 6.
Treatment Algorithm by Disease Severity
Mild Disease (skin, joints, constitutional symptoms)
- Start: HCQ + low-dose glucocorticoids (GC)
- If inadequate response: Add methotrexate (strongest evidence, 1b/B), azathioprine, or mycophenolate 5
- For cutaneous disease specifically: Topical glucocorticoids or calcineurin inhibitors + HCQ; if refractory, add methotrexate, retinoids, dapsone, or mycophenolate 5
Moderate Disease (inadequate response to standard therapy, frequent relapses, inability to taper glucocorticoids)
Add belimumab (anti-BAFF biologic)—this has Level 1a/A evidence and is the preferred biologic for patients not responding to HCQ + GC ± immunosuppressives 5. Belimumab allows glucocorticoid tapering and reduces flare rates.
Severe/Organ-Threatening Disease
Lupus Nephritis (most critical to recognize early):
- Perform renal biopsy when proteinuria or active sediment present 5
- Induction therapy: Mycophenolate (1a/A) OR low-dose IV cyclophosphamide (2a/B)—these have the best efficacy/toxicity ratio 5
- For high-risk patients (reduced GFR, crescents, fibrinoid necrosis on biopsy): consider high-dose IV cyclophosphamide 5
- Maintenance therapy: Mycophenolate (1a/A) or azathioprine (1a/A) 5
- Combine with pulse IV methylprednisolone (250-1000 mg/day for 1-3 days) followed by oral prednisone taper 5
Neuropsychiatric SLE:
- First distinguish SLE-related from non-SLE causes (use neuroimaging, CSF analysis, exclude infections/metabolic causes) 5
- For inflammatory manifestations: high-dose GC + immunosuppressives 5
- For thrombotic/antiphospholipid-related: anticoagulation 5
Severe Thrombocytopenia:
- High-dose GC (including IV methylprednisolone pulses) and/or IVIG 5
- Maintenance: mycophenolate, azathioprine, or cyclosporine 5
- Refractory cases: rituximab or cyclophosphamide 5
Life-Threatening/Refractory Disease:
- Cyclophosphamide for rescue therapy 5
- Rituximab (anti-CD20) for organ-threatening disease refractory to standard immunosuppressives 5
Emerging Biologics
Anifrolumab (type I interferon receptor antagonist) has proven efficacy in high-quality RCTs with organ-specific endpoints and is now approved 6. This represents a major advance for patients with high interferon signature.
Critical Monitoring and Pitfalls
HCQ retinal toxicity: Screen at baseline, after 5 years, then yearly with visual fields and/or spectral domain-OCT 5. Risk increases with cumulative dose and duration—stay under 5 mg/kg/day 6.
Glucocorticoid toxicity: The evidence is unequivocal—chronic GC use above 5 mg/day causes cumulative damage 6. Aggressively add steroid-sparing agents early rather than maintaining patients on moderate-dose prednisone.
Antiphospholipid syndrome: Screen ALL patients at diagnosis for antiphospholipid antibodies 5. High-risk profiles (persistently positive medium/high titers or multiple positivity) may warrant primary prophylaxis with antiplatelet agents, especially with other cardiovascular risk factors 5.
Infection risk: Patients on immunosuppression require vaccination (including recombinant zoster vaccine, which is safe with only 5.5% flare rate and <2% moderate/severe flares; SARS-CoV-2 vaccines show 81% seropositivity with similar low severe flare rates) 6.
Pregnancy: Requires specialized management—hydroxychloroquine should be continued, but many immunosuppressives require adjustment.
Treat-to-Target Strategy
The modern approach emphasizes structured monitoring with defined treatment targets 1, 7, 8. Adjust therapy based on disease activity indices (SLEDAI, BILAG), aiming for remission or low disease activity. Flares should trigger immediate intensification—increase GC temporarily, switch or add immunosuppressives, or escalate to biologics 5.
The key paradigm shift: minimize glucocorticoid exposure while maximizing disease control through early, aggressive use of steroid-sparing agents and biologics 6, 1.